Isosorbide oral solution not checked
Lunan Better Pharmaceutical Co., LTD.
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Meniere´s Disease
- Main trialPhase 2/3
- “The purpose of this study is to evaluate the efficacy and safety of isosorbide oral solution compared with placebo in people with unilateral Meniere's disease. A total of approximately 234 subjects will be enrolled in this study: 72 subjects in phase Ⅱ and approximately 162 subjects in phase Ⅲ. Patients were randomly assigned to either the experimental group or the control group. The randomization ratios for phase Ⅱ and phase Ⅲ were 1:1 and 2:1, respectively.”In the company’s words, NCT06765993 on ClinicalTrials.gov
Other drugs for Meniere´s Disease
- EbselenSound Pharmaceuticals, Incorporated · Phase 3
- LY888891Eli Lilly · Phase 3
- KP-100ITKringle Pharma, Inc. · Phase 3
- N-Acetylcysteine AmideNacuity Pharmaceuticals, Inc. · Phase 3
- SonlicromanolKhondrion BV · Phase 3
- KP-100LIKringle Pharma, Inc. · Phase 3
Coming up1
- 30 Jun 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 30 Jun 2027 | Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026